Enveda announced milestones from Boulder, Colo., securing Series D funding from Baillie Gifford and welcoming Mikael Dolsten to its Board of Directors.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Enveda announced milestones from Boulder, Colo., securing Series D funding from Baillie Gifford and welcoming Mikael Dolsten to its Board of Directors.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Enveda
Biotechnology Company in Boulder (CO)
Nothing else this week.
-
Mikael Dolsten
Swedish-American doctor, business executive & corporate director; Chief Scientific Officer, Pfizer
Nothing else this week.
-
Baillie Gifford
investment management firm
Coverage
Newest first; wire copies grouped- Business WireEnveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors Pipeline expansion: Company advances first-in-class